Bladder cancer drug payment cuts have urologists seeing red

Why This Topic Matters

The article highlights reimbursement shifts that may affect drug administration economics in urology practices and shows how CMS policy changes can influence practice operations, patient access, and specialty advocacy.

Article Sections

1. Medicare reimbursement changes and urology concerns

   This section discusses upcoming Medicare payment changes, specialty-level reimbursement impacts, and concerns raised by urology representatives. It also introduces CMS policy changes tied to the Medicare Modernization Act.

2. CMS and specialty society discussion

   This section summarizes comments from CMS officials and responses from urology stakeholders about drug pricing, payment methodology, and practice concerns. It also mentions CMS outreach and the role of specialty societies.

3. Policy issues affecting drug administration

   This section covers broader Medicare drug payment policy topics discussed by urologists, including competitive bidding and least costly alternative concerns. It describes the policy context without giving operational coding guidance.

4. Table: Urologists expect to see large cuts in payment for bladder cancer drugs

   This section presents a comparison table of selected drugs, their HCPCS codes, and related payment and purchase-price information. It provides the article’s summarized reimbursement data for the drugs discussed.